Novo Nordisk makes a comeback, stating that the cardiovascular benefits of the weight-loss version of semaglutide are superior to those of tirzepatide

Zhitong
2025.09.01 06:33

In the competition of GLP-1 weight loss drugs, Novo Nordisk's semaglutide has finally turned the tide with its cardiovascular benefits. On September 1st, reporters learned from Novo Nordisk China that the company announced the latest data from the STEER real-world study at the 2025 European Society of Cardiology Congress held in Madrid, Spain. The STEER study is a retrospective, observational real-world study that evaluated the effectiveness of Wegovy compared to tirzepatide in preventing major adverse cardiovascular events in overweight or obese patients with diagnosed cardiovascular disease but without diabetes. The results showed that, under the condition that the medication interruption during treatment did not exceed 30 days, the weight loss version of semaglutide reduced the risk of heart attack, stroke, and cardiovascular-related death or all-cause mortality by 57% compared to tirzepatide in overweight or obese patients with cardiovascular disease. In the trial, the semaglutide group recorded 15 cardiovascular events, while the tirzepatide group recorded 39 events

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.